Wang, J.

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2015) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 464

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Chen, G., Feng, J., Zhou, C., Wu, Y.-L., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2013) · Annals of Oncology

Lung Cancer Treatments and MutationsCancer survivorship and care

Cited by 121

Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib: the Phase Iii, Randomised Impress Study

Mok, T. S. K., Wu, Y., Nakagawa, K., Kim, S., Yang, J., Ahn, M., Wang, J., Yang, J. C., Lu, Y., Atagi, S., et al. (2014) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 46